

# Medicare Medical Policy

---

## Radiofrequency Ablation of Tumors Outside the Liver

MEDICARE MEDICAL POLICY NUMBER: 377

---

**Effective Date:** 1/1/2026

MEDICARE COVERAGE CRITERIA.....	2
POLICY CROSS REFERENCES.....	3
POLICY GUIDELINES.....	3
REGULATORY STATUS.....	4
BILLING GUIDELINES AND CODING .....	4
REFERENCES.....	5
POLICY REVISION HISTORY.....	6

**Last Review Date:** 12/2025

**Next Annual Review:** 12/2026

**INSTRUCTIONS FOR USE:** Company Medicare Medical Policies serve as guidance for the administration of plan benefits and do not constitute medical advice nor a guarantee of coverage. Company Medicare Medical Policies are reviewed annually to guide the coverage or non-coverage decision-making process for services or procedures in accordance with member benefit contracts (otherwise known as Evidence of Coverage or EOCs) and Centers of Medicare and Medicaid Services (CMS) policies, manuals, and other CMS rules and regulations. In the absence of a CMS coverage determination or specific regulation for a requested service, item or procedure, Company policy criteria or applicable utilization management vendor criteria may be applied. These are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

The Company reserves the right to determine the application of Medicare Medical Policies and make revisions to these policies at any time. Any conflict or variance between the EOC and Company Medical Policy will be resolved in favor of the EOC.

**SCOPE:** Providence Health Plan, Providence Health Assurance, and Providence Plan Partners as applicable (referred to individually as "Company" and collectively as "Companies").

## PRODUCT AND BENEFIT APPLICATION

Medicare Only

### MEDICARE COVERAGE CRITERIA

**IMPORTANT NOTE:** More than one Centers for Medicare and Medicaid Services (CMS) reference may apply to the same health care service, such as when more than one coverage policy is available (e.g., both an NCD and LCD exist). All references listed should be considered for coverage decision-making. The Company uses the most current version of a Medicare reference available at the time of publication; however, these websites are not maintained by the Company, so Medicare references and their corresponding hyperlinks may change at any time. If there is a conflict between the Company Medicare Medical Policy and CMS guidance, the CMS guidance will govern.

**Notes:**

- This policy does not address liver tumors (primary or metastatic). See the separate Medical Policy for “Liver Tumor Treatment” for further information.
- This policy is specific to **radiofrequency ablation** (RFA) techniques only. Other ablative procedures (laser therapy, cryotherapy, etc.) used in the treatment of tumors which are not addressed by this medical policy may be considered medically necessary unless otherwise stated by a separate Medicare medical policy.

Service	Medicare Guidelines
<p><b>Medicare Coverage Criteria:</b> “MA organizations may create publicly accessible internal coverage criteria... when coverage criteria are not fully established in applicable Medicare statutes, regulations, NCDs or LCDs.” (§ 422.101(b)(6) – see <a href="#">Policy Guidelines</a> below)</p> <ul style="list-style-type: none"><li>• <b>Medicare Coverage Manuals:</b> Medicare does not have criteria for radiofrequency ablation (RFA) of non-liver tumors in a coverage manual.</li><li>• <b>National Coverage Determination (NCD):</b> Medicare does not have an NCD for RFA of non-liver tumors.</li><li>• <b>Noridian J-F Local Coverage Determination (LCD)/Local Coverage Article (LCA):</b> As of the most recent policy review, no Medicare Administrative Contractors (MACs) have LCDs for RFA of non-liver tumors.</li><li>• Therefore, in the absence of established Medicare coverage criteria in a manual, NCD, LCD, or other regulatory guidance for the health plan’s service area, Company criteria below are applied for medical necessity decision-making. In this case, Medicare coverage criteria are considered “not fully established” as defined under CFR § 422.101(6)(i)(C) as there is no Medicare coverage criteria available.</li><li>• <b>NOTE:</b> <i>The summary of evidence, as well as the list of citations/references used in the development of the Company’s internal coverage criteria, are publicly available and can be found using the Company medical policy link below [CFR § 422.101(6)(ii)(A) and (B)].</i></li></ul>	
<i>RFA of the following Non-Liver Tumors:</i>	Company medical policy for <a href="#">Radiofrequency Ablation of Tumors Outside the Liver</a>

<ul style="list-style-type: none"> <li>• <i>Bone</i></li> <li>• <i>Breast</i></li> <li>• <i>Thyroid</i></li> <li>• <i>Colon</i></li> <li>• <i>Kidney</i></li> <li>• <i>Non-small cell lung cancer</i></li> <li>• <i>Uterine Fibroids (58580/58674)</i></li> </ul>	<p>I. These services may be considered <b>medically necessary</b> for Medicare when the Company medical policy criteria are met.</p> <p>II. These services are considered <b>not medically necessary</b> for Medicare Plan members either when the Company medical policy criteria are <b>not met</b> <i>or</i> when a service is deemed “not medically necessary” by the Company policy. <u>See Policy Guidelines below.</u></p>
---	---

**IMPORTANT NOTICE:** While some services or items may appear medically indicated for an individual, they may also be a direct exclusion of Medicare or the member's benefit plan. Such excluded services or items by Medicare and member EOCs include, but are not limited to, services or procedures considered to be cosmetic, not medical in nature, or those considered not medically reasonable or necessary under *Title XVIII of the Social Security Act, §1862(a)(1)(A)*. If there is uncertainty regarding coverage of a service or item, please review the member EOC or submit a pre-service organization determination request. Note that the Medicare Advance Beneficiary Notice of Noncoverage (ABN) form **cannot** be used for Medicare Advantage members. (*Medicare Advance Written Notices of Non-coverage. MLN006266 May 2021*)

## POLICY CROSS REFERENCES

- [Liver Tumor Treatment](#), MP265
- [Microwave Thermotherapy for Breast Cancer](#), MP68

The full Company portfolio of Medicare Medical Policies is available online and can be [accessed here](#).

## POLICY GUIDELINES

### Medicare and Medical Necessity

Only medically reasonable and necessary services or items which treat illness or injury are eligible for Medicare coverage, as outlined in *Title XVIII of the Social Security Act, §1862(a)(1)(A)*. MA organizations (MAOs) make medical necessity determinations based on coverage and benefit criteria, current standards of care, the member's unique personal medical history (e.g., diagnoses, conditions, functional status, co-morbidities, etc.), physician recommendations, and clinical notes, as well as involvement of a plan medical director, where appropriate. (*§ 422.101(c)(1)*)

In addition:

“MA organizations may create publicly accessible internal coverage criteria that are based on current evidence in widely used treatment guidelines or clinical literature when coverage criteria are not fully established in applicable Medicare statutes, regulations, NCDs or LCDs. Current, widely-used treatment guidelines are those developed by organizations representing clinical medical specialties, and refers to guidelines for the treatment of specific diseases or conditions. Acceptable clinical literature includes large, randomized controlled trials or prospective cohort studies with clear results, published in a peer-reviewed journal, and specifically designed to answer the relevant clinical question, or large systematic reviews or

meta-analyses summarizing the literature of the specific clinical question." (*§ 422.101(b)(6) and Medicare Managed Care Manual, Ch. 4, §90.5*)

The Plan's Medicare policy for *PHA Medicare Medical Policy Development and Application* ([MP50](#)) provides details regarding Medicare's definition of medical necessity and the hierarchy of Medicare references and resources during the development of medical policies, as well as the Plan's use of evidence-based processes for policy development.

Since there are not fully established coverage criteria for radiofrequency ablation (RFA) of **non-liver** tumors available in applicable Medicare statutes, regulations, NCDs or LCDs, then Company medical policy criteria will be applied. See the [Medicare Coverage Criteria](#) table above for more information regarding the use of internal coverage criteria when Medicare coverage criteria are not fully established.

## REGULATORY STATUS

### U.S. FOOD & DRUG ADMINISTRATION (FDA)

While clearance by the Food and Drug Administration (FDA) is a prerequisite for Medicare coverage, the 510(k) premarket clearance process does not in itself establish medical necessity. Medicare payment policy is determined by the interaction of numerous requirements, including but not limited to, the availability of a Medicare benefit category and other statutory requirements, coding and pricing guidelines, as well as national and local coverage determinations and clinical evidence.

## BILLING GUIDELINES AND CODING

### GENERAL

#### Transbronchial Lung Cryobiopsy

- **Cryobiopsy** – A technique used to obtain a tissue sample for further evaluation.
- **Cryotherapy** – Aka, cryoablation. Intended to destroy a lesion or tumor as a treatment of the lesion/tumor in question.

*Neither of these services are addressed by this medical policy, as it is limited to radiofrequency ablation techniques to destroy non-liver tumors and lesions.*

CPT code 31641 describes a **destruction** service – a bronchoscopy procedure to destroy a tumor or provide relief of stenosis. It does not describe obtaining a biopsy sample, by any method, including the use of cryo techniques. Therefore, CPT code 31641 should **not** be used to report for transbronchial lung cryobiopsy. Rather, the more appropriate code choice for transbronchial biopsy (regardless of the technique used; i.e., needle, forceps, cryo, etc.) will likely be CPT 31628 and/or 31632, depending on the number of lobes involved. Note that CPT codes 31628/31632 are not addressed by any medical policy.

## CODES\*

CPT	19499	Unlisted procedure, breast
-----	-------	----------------------------

	20982	Ablation therapy for reduction or eradication of 1 or more bone tumors (eg, metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; radiofrequency
	31641	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with destruction of tumor or relief of stenosis by any method other than excision (eg, laser therapy, cryotherapy)
	32998	Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; radiofrequency
	32999	Unlisted procedure, lungs and pleura
	45399	Unlisted procedure, colon
	50542	Laparoscopy, surgical; ablation of renal mass lesion(s), including intraoperative ultrasound guidance and monitoring, when performed
	50549	Unlisted laparoscopy procedure, renal
	50592	Ablation, 1 or more renal tumor(s), percutaneous, unilateral, radiofrequency
	58580	Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency
	58674	Laparoscopy, surgical, ablation of uterine fibroid(s) including intraoperative ultrasound guidance and monitoring, radiofrequency
	60660	Ablation of 1 or more thyroid nodule(s), one lobe or the isthmus, percutaneous, including imaging guidance, radiofrequency
	60661	Ablation of 1 or more thyroid nodule(s), additional lobe, percutaneous, including imaging guidance, radiofrequency (List separately in addition to code for primary procedure)
	60699	Unlisted procedure, endocrine system
<b>HCPCS</b>	None	

**\*Coding Notes:**

- The code list above is provided as a courtesy and may not be all-inclusive. Inclusion or omission of a code from this policy neither implies nor guarantees reimbursement or coverage. Some codes may not require routine review for medical necessity, but they are subject to provider contracts, as well as member benefits, eligibility and potential utilization audit. According to Medicare, “presence of a payment amount in the MPFS and the Medicare physician fee schedule database (MPFSDB) does not imply that CMS has determined that the service may be covered by Medicare.” The issuance of a CPT or HCPCS code or the provision of a payment or fee amount by Medicare does not make a procedure medically reasonable or necessary or a covered benefit by Medicare. (*Medicare Claims Processing Manual, Chapter 23 - Fee Schedule Administration and Coding Requirements, §30 - Services Paid Under the Medicare Physician's Fee Schedule, A. Physician's Services*)
- All unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is submitted for non-covered services addressed in this policy then it will be **denied as not covered**. If an unlisted code is submitted for potentially covered services addressed in this policy, to avoid post-service denial, **prior authorization is recommended**.
- See the **non-covered and prior authorization lists on the Company [Medical Policy, Reimbursement Policy, Pharmacy Policy and Provider Information website](#)** for additional information.
- HCPCS/CPT code(s) may be subject to National Correct Coding Initiative (NCCI) procedure-to-procedure (PTP) bundling edits and daily maximum edits known as “medically unlikely edits” (MUEs) published by the Centers for Medicare and Medicaid Services (CMS). This policy does not take precedence over NCCI edits or MUEs. Please refer to the CMS website for coding guidelines and applicable code combinations.

## REFERENCES

None

## POLICY REVISION HISTORY

DATE	REVISION SUMMARY
4/2023	New Medicare Advantage medical policy
8/2023	Interim update, added relevant unlisted code
1/2024	Q1 2024 code update and Interim update; with updated Company medical policy medically necessary criteria, update criteria for RFA of uterine fibroids for Medicare
2/2024	Annual review, no change to criteria
1/2025	Annual review and Q1 2025 code update
1/2026	Annual review, no change to criteria